888-430-5470
  • Facebook
  • Twitter
  • Google
  • Facebook
  • Twitter
  • Google
Drug Outlook
  • Drugs & Devices
    • Actos
    • Benicar
    • Da Vinci Robots
    • Essure
    • Granuflo
    • Hip Implants
    • INFUSE® Bone Graft
    • IVC Filters
    • Physiomesh
    • Power Morcellator
    • Pradaxa
    • Risperdal
    • SGLT2 Inhibitors
    • Talcum Powder
    • Testosterone Therapy
    • Transvaginal Mesh
    • Viagra
    • Xarelto
    • Zofran
  • Manufacturers
    • AbbVie & Abbott
    • Boehringer Ingelheim
    • Eli Lilly
    • GlaxoSmithKline
    • Takeda Pharma
  • Current Lawsuits
    • Case Evaluation
  • News
  • DrugHub©
Select Page

Price-Gouging for Profit: The Rise and Fall of Valeant

by Mooslet Writing Services | Jun 30, 2016 | Uncategorized

The rise and fall of Valeant Pharmaceuticals may be a teachable moment for the entire pharma industry: gouge the public at your peril. On July 31, 2015, the Canadian company seemed like a pharma dream come true. On that date, Valeant’s stock price hit an all-time high...

Drug Wholesalers Settle Opioid Lawsuit

by Mooslet Writing Services | Jun 28, 2016 | Big Pharma Lawsuits

West Virginia state agencies have settled half their lawsuits against drug wholesalers accused of illegally supplying opioids. So far, the settlements have totaled $6.7 million from six different pharmaceutical distributors: Miami-Luken – $2.5 million Anda...

Lawmakers Fight To Improve Access to Generic Drugs

by Mooslet Writing Services | Jun 27, 2016 | Prescription Drugs

Lawmakers from both houses on Capitol Hill are taking aim at obstructionary practices used by brand-name pharmaceutical companies against would-be makers of generic drugs. In the Senate, a bipartisan group comprised of members from the Judiciary Committee and its...

Million-Dollar Drugs: Gene Therapy No One Can Afford

by Mooslet Writing Services | Jun 23, 2016 | Clinical Trials

What is the value of being able to see? If it costs a half a million dollars per eye to cure genetic blindness, would you do it? Now, let’s make the scenario more complex. Let’s say a cure for hemophilia B would run you $4 million upfront. Would you instead agree to...

WHO Endorses Olympics Despite Zika Virus

by Mooslet Writing Services | Jun 21, 2016 | Consumer Healthcare

The World Health Organization (WHO) recently announced that fears about the mosquito-borne Zika virus should not halt the Olympic Games in Rio de Janeiro, Brazil. The global health organization said that athletes and visitors should go forward with their travel plans....

Pharmaceutical Sales Reps Arrested by FBI

by Mooslet Writing Services | Jun 20, 2016 | Prescription Drugs

First, it was propofol,  the drug that killed Michael Jackson. Then came fentanyl, which killed pop icon Prince. If the pharmaceutical industry has its way, deaths from prescription drugs like these are not likely to decrease anytime soon. The latest pharma scandal to...

Merck Wins Drug Patent Lawsuit but Fails to Collect

by Mooslet Writing Services | Jun 16, 2016 | Big Pharma Lawsuits

A recent battle of pharmaceutical heavyweights Gilead and Merck has resulted in both companies walking away with a black eye. The dispute over a hepatitis C drug patent showed Gilead as the clear loser but also denied Merck its $200 million winning settlement....

Delaware Increases Access to Hepatitis C Medicines

by Mooslet Writing Services | Jun 14, 2016 | Uncategorized

Delaware state health officials have agreed to change the state’s Medicaid guidelines to make it easier for patients to get Hepatitis C medicine. The move comes as a result of a demand letter sent to Delaware state officials by the Center for Health Law and Policy...

Tarceva Lawsuit Results In $67 Million Settlement

by Mooslet Writing Services | Jun 13, 2016 | Big Pharma Lawsuits

The US Department of Justice (DOJ) recently announced that it had reached a $67 million settlement with two pharmaceutical companies over alleged false claims made about cancer drug Tarceva. Pharma Companies Misled Doctors for Six Years The lawsuit was brought about...

Samsung’s Pharma Arm Joins the US Biosimilars Race

by Mooslet Writing Services | Jun 9, 2016 | Big Pharma Business

There’s a new face in the crowded pharmaceutical marketplace – Samsung. The mobile technology juggernaut responsible for Galaxy smartphones is diversifying into the lucrative biosimilar pharmaceutical business.   Samsung already makes medical devices like...
« Older Entries

Recent Posts

  • Price-Gouging for Profit: The Rise and Fall of Valeant
  • Drug Wholesalers Settle Opioid Lawsuit
  • Lawmakers Fight To Improve Access to Generic Drugs
  • Million-Dollar Drugs: Gene Therapy No One Can Afford
  • WHO Endorses Olympics Despite Zika Virus

Recent Comments

  • Namaste927 on Lioresal
  • Mietzekatze on Maxzide
  • Jack on Zyloprim

Archives

  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • October 2015

Categories

  • Big Pharma Business
  • Big Pharma Lawsuits
  • Clinical Trials
  • Consumer Healthcare
  • FDA
  • Prescription Drugs
  • Uncategorized

Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

THIS IS A PAID ATTORNEY/ADVOCATE ADVERTISEMENT. This website is a group advertisement and a fee is paid for by participating attorneys and advocates. The site is not an attorney referral service or prepaid legal services plan. The information provided by Drug Outlook is not a substitute for professional medical advice, diagnosis or treatment. The views and opinions expressed on the site do not necessarily represent those of Drug Outlook. This website does not make any representation to the qualifications, expertise or credentials of participating attorneys/advocates and does not represent that quality is better than services performed by other attorneys/advocates. Any information you submit to this website may not be protected by attorney-client privilege. An automated matching system will match each request with a member attorney/advocate representing the specific geography.

If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of "Fair Use" and legitimately infringes on yours or your client's copyright, we may be contacted concerning copyright matters at: [email protected]

©2015 DrugOutlook.com. View our Terms of Use or Privacy Policy.